Palmović D, Vitas B, Doko A, Belavić Z, Racki L
Lijec Vjesn. 1989 Nov;111(11):400-4.
Hepatitis B remains a significant risk to patients and staff members of hemodialysis unit. Prior to immunization, 38 hemodialysis patients and 24 staff members were screened for HBs antigen, HBc antibodies and HBs antibodies using ELISA method (Abbott). Of 18 (47%) patients, five were chronic carriers of HBsAg and 13 had anti-HBs and anti-HBc while anti-HBs and anti-HBc were found in four (17%) members of medical staff. A total of 20 (53%) susceptible patients (mean 51.2 years) and 19 (79%) susceptible staff members (mean 28.1 years) received hepatitis B vaccine (H-B-VAX, Merck, Sharp and Dohme). Between patients were four (20%) non-responders and seven (35%) low-responders while among medical staff were two (10.5%) non-responders and one (5.2%) low responder only. The geometric mean titer of anti-HBs was 724 IU/L in patients and 3407 IU/L in staff members. Non-responders (5 of 6) who were given a fourth vaccine dose also failed to mount an antibody response. In none of vaccinated patients antibody to human immunodeficiency virus (HIV-1) occurred in their sera three and six months after complete vaccination. Consideration should be given to a prevaccinal screening of presumptive vaccinees between patients and staff members of hemodialysis units because of high level of preexisting HBV infection among them. The data suggest a high non-responder and low-responder rate in vaccinated hemodialysis patients and serial surveillance for anti-HBs is warranted especially in persons aged over 40 years. Additional booster dose or some doses of HB vaccine should be given to low-responders and they should be retested thereafter. Non-responders still remain the unresolved problem.
乙型肝炎对血液透析单位的患者和工作人员仍然构成重大风险。在接种疫苗之前,使用酶联免疫吸附测定法(雅培公司)对38名血液透析患者和24名工作人员进行了乙肝表面抗原、乙肝核心抗体和乙肝表面抗体筛查。在18名(47%)患者中,5名是乙肝表面抗原慢性携带者,13名有乙肝表面抗体和乙肝核心抗体,而在4名(17%)医务人员中发现了乙肝表面抗体和乙肝核心抗体。共有20名(53%)易感患者(平均年龄51.2岁)和19名(79%)易感工作人员(平均年龄28.1岁)接种了乙肝疫苗(H-B-VAX,默克公司、夏普公司和多姆公司)。患者中有4名(20%)无应答者和7名(35%)低应答者,而医务人员中只有2名(10.5%)无应答者和1名(5.2%)低应答者。患者中乙肝表面抗体的几何平均滴度为724国际单位/升,工作人员中为3407国际单位/升。接受第四剂疫苗的无应答者(6人中的5人)也未能产生抗体反应。在所有接种疫苗的患者中,接种完全程疫苗后3个月和6个月,其血清中均未出现抗人类免疫缺陷病毒(HIV-1)抗体。由于血液透析单位的患者和工作人员中既往乙肝病毒感染率较高,应考虑对假定的疫苗接种者进行接种前筛查。数据表明,接种疫苗的血液透析患者中无应答者和低应答者比例较高,尤其是40岁以上人群,有必要对乙肝表面抗体进行连续监测。应给低应答者额外接种加强剂量或一些剂量的乙肝疫苗,之后还应重新检测。无应答者仍然是一个未解决的问题。